关键词：单克隆抗体（mAb）；不稳定；化学交联剂；癌症；杀死细胞毒性药物；能力
摘 要：ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

Assumptions

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Overview of ADCs

Antibodies

Evolution of mAb therapeutics

Conjugated mAbs

History

Key components in ADCs

Next-generation ADCs

Advantages

Challenges

Outsourcing of ADCs manufacturing

Emergence of ADCs

Current marketed ADCs

PART 06: Pipeline portfolio

Information on pipeline candidates

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by MOA

IgG1 antibodies

HER2 antibodies

PART 09: Market segmentation by technologies used in

ADCs

Seattle Genetics (SGEN) technology

ImmunoGen (IMGN) technology

Immunomedics (IMMU) technology

PART 10: Geographical segmentation

PART 11: Market drivers

Robust late-stage pipeline

Rising prevalence of cancers

Increase in demand for antibody conjugates

Reimbursement policies

PART 12: Impact of drivers

PART 13: Market challenges

High developmental costs

Stringent regulations

Risk of side effects

PART 14: Impact of drivers and challenges

PART 15: Market trends

Strategic alliances

Increased outsourcing of drug development

Emergence of targeted and combination therapies

PART 16: Vendor landscape

Competitive scenario

Key news

F. Hoffmann-La Roche

Seattle Genetics

Takeda Pharmaceuticals

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio